Transcriptomic analysis of the cell lines discovered significantly upregulated GBP1 expression in both cell lines, compared to the parental cells, with 6.78- and 8.78-fold changes for the ethidium bromide treated cell line and the flavopiridol treated cell line, respectively, strongly indicating a oncogenic role of GBP1 in prostate cancer cells. This evidence concerns the gene GBP1 and prostate carcinoma.